We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) (OPTIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02968901
Recruitment Status : Terminated
First Posted : November 21, 2016
Last Update Posted : October 8, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-naïve patients with newly diagnosed pulmonary arterial hypertension (PAH).

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: macitentan Drug: tadalafil Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).
Actual Study Start Date : September 1, 2015
Actual Primary Completion Date : September 10, 2018
Actual Study Completion Date : September 10, 2018

Arm Intervention/treatment
Experimental: bitherapy
Macitentan and tadalafil
Drug: macitentan
used in open label

Drug: tadalafil
used in open label

Primary Outcome Measures :
  1. pulmonary vascular resistance (PVR) [ Time Frame: 16 weeks ]
    Change from Baseline to Week 16 in percentage of patients with clinically meaningful improvement of PVR (decrease of 30% from baseline to Week 16)

Secondary Outcome Measures :
  1. mean right atrial pressure (mRAP) [ Time Frame: Week 16 ]
    Change from Baseline to Week 16 in mean right atrial pressure (mRAP)

  2. 6MWD [ Time Frame: Week 16 ]
    Change from Baseline to Week 16 in 6MWD

  3. level NT-proBNP [ Time Frame: Week 16 ]
    Change in NT-proBNP from baseline to Week 16

  4. mean pulmonary arterial pressure (mPAP) [ Time Frame: Week 16 ]
    Change from Baseline to Week 16 in mean pulmonary arterial pressure (mPAP)

  5. cardiac index (CI) [ Time Frame: Week 16 ]
    Change from Baseline to Week 16 in cardiac index (CI).

  6. total pulmonary resistance (TPR) [ Time Frame: Week 16 ]
    Change from Baseline to Week 16 in total pulmonary resistance (TPR)

  7. mixed venous oxygen saturation (Sv02) [ Time Frame: Week 16 ]
    Change from Baseline to Week 16 in mixed venous oxygen saturation (Sv02)

  8. WHO functional class [ Time Frame: Week 16 ]
    Change from baseline to Week 16 in WHO functional class and Percentage of patients with improvement/worsening of WHO functional class from baseline to Week 16

  9. Number of treatment goals [ Time Frame: Week 16 ]
    Number of treatment goals (score 0 or 1 per goal, i.e. total score 0-5) met at Week 16: WHO-FC I or II; Cardiac index > 2.8 L/min/m²; mRAP < 8 mmHg; 6MWD > 400 m; NT-proBNP < 3xULN

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria :

  1. Signed informed consent prior to any study-mandated procedure.
  2. Male or female ≥ 18 and ≤ 75 years of age at screening.
  3. Initial PAH diagnosis < 6 months prior to Day 1.
  4. Right heart catheterization (RHC) performed between Day -28 and Day 1 (RHC data obtained at the study site within this time frame, but before the study, i.e., before signed informed consent, are acceptable), meeting all the following criteria:

    • Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg.
    • Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg.
    • PVR ≥ 400 dyn·sec/cm5 (≥ 5 Wood units) if PCWP < 12 mmHg OR PVR ≥ 500 dyn·sec/cm5 (≥ 6.25 Wood units) if PCWP in [12-15] mmHg.
    • Negative vasoreactivity test mandatory in idiopathic PAH (at this or a previous RHC).
  5. World Health Organization (WHO) Functional Class (FC) II to III.
  6. PAH etiology belonging to one of the following groups:

    • Idiopathic.
    • Heritable.
    • Anorexigens induced.
    • Associated with one of the following:

      • Connective tissue disease
      • Congenital heart disease with simple systemic-to-pulmonary shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus) ≥1 year after surgical repair
      • HIV infection
  7. 6MWD ≥ 50 m at screening.
  8. Woman of childbearing potential [see definition in Section 4.5.1] must:

    • Have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the D1 visit, and
    • Agree to perform monthly pregnancy tests up to 30 days after EOT2, and
    • Agree to use reliable contraception [defined in Section 4.5.2] from screening up to 30 days after EOT2. Reliable contraception must be started at least 11 days prior to Day 1.

Exclusion Criteria:

  1. Any PAH-specific drug therapy [e.g. any endothelin receptor antagonist, phosphodiesterase-5 inhibitors (PDE-5i), soluble guanylate cyclase stimulator, prostacyclin, prostacyclin analog, or prostacyclin receptor agonist] at any time prior to Day 1 (single-dose administration for vasoreactivity testing is permitted; previous iloprost used intermittently for the treatment of digital ulcers or Raynaud's phenomenon is permitted if stopped > 6 months prior to Day 1).
  2. Subjects who changed the dose or discontinued calcium channel blockers within 1 week prior to Day 1.
  3. Initiation of diuretics within 1 week prior to RCH.
  4. Subjects on oral diuretics in whom the dose has not been stable for at least 1 week prior to RHC.
  5. Treatment with other PDE-5i for erectile dysfunction.
  6. Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤ 28 days prior to Day 1.
  7. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, boceprevir, telaprevir, saquinavir, lopinavir, fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, indinavir) ≤ 28 days prior to Day 1.
  8. History of priapism.
  9. Significant aortic and mitral valve disease requiring a specific treatment.
  10. Pericardial constriction.
  11. Life-threatening arrhythmia.
  12. Uncontrolled hypertension.
  13. Symptomatic coronary artery disease.
  14. Cardio-pulmonary rehabilitation program based on exercise (planned, or started ≤ 12 weeks prior to Day 1).
  15. Body mass index (BMI) > 40 kg/m2 at screening.
  16. Acute myocardial infarction ≤ 12 weeks prior to Day 1.
  17. Known permanent atrial fibrillation.
  18. Low blood pressure < 90/50 mmHg at screening or Day 1.
  19. Ongoing or planned treatment with nitrates and/or doxazosin.
  20. DLCO < 40% of predicted value (eligible only if no sign of veno-occlusive disease according to adjudication committee);
  21. Presence of ≥ 1 of the following signs of relevant lung disease at any time prior to Day 1:

    • FEV1/FVC < 70% and FEV1 < 65% of predicted after bronchodilator administration;
    • Total Lung Capacity (TLC) < 60% of predicted.
  22. Known or suspicion of pulmonary veno-occlusive disease (PVOD).
  23. Severe renal insufficiency (estimated creatinine clearance ≤ 30 mL/min/1.73m²) assessed by central laboratory at screening.
  24. Ongoing or planned dialysis.
  25. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin > 3 x ULN accompanied by AST > ULN (assessed by central laboratory at screening) and/or Child-Pugh Class C.
  26. Serum AST and/or ALT > 3 x ULN (assessed by central laboratory at screening).
  27. Porto-pulmonary hypertension.
  28. Hemoglobin < 100 g/L assessed by central laboratory at screening.
  29. Hypersensitivity to any active substance or excipient of macitentan or tadalafil formulation.
  30. Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether or not this episode was in connection with previous PDE-5i exposure.
  31. Hereditary degenerative retinal disorders, including retinitis pigmentosa.
  32. Pregnancy, breast-feeding, intention to become pregnant during the study or woman of childbearing potential not agree to use reliable method of contraception from screening up to 30 days after EOT2.
  33. Hereditary problems of galactose intolerance, Lapp lactase deficiency, glucosegalactose malabsorption.
  34. Any factor or condition likely to affect protocol compliance of the patient as judged by the investigator.
  35. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to Day 1).
  36. Concomitant life-threatening disease with a life expectancy < 12 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02968901

Show Show 18 study locations
Sponsors and Collaborators
Additional Information:
Layout table for additonal information
Responsible Party: Actelion
ClinicalTrials.gov Identifier: NCT02968901    
Other Study ID Numbers: AC-055-405
First Posted: November 21, 2016    Key Record Dates
Last Update Posted: October 8, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Arterial Hypertension
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Endothelin B Receptor Antagonists